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The innate immune system is equipped with pattern-recognition 
receptors that recognize pathogen-associated molecular patterns1. 
Pattern-recognition receptors include transmembrane Toll-like recep-
tors (TLRs) and cytosolic Nod-like receptors2. Nod1 and Nod2 recog-
nize structures in bacterial peptidoglycan3. Loss-of-function mutants 
of Nod2 are associated with Crohn’s disease4–6, whereas gain-of-
 function mutants result in predisposition to the development of early-
onset sarcoidosis and Blau syndrome7,8. Nod2 responds to muramyl 
dipeptide (MDP), a derivative of peptidoglycan9,10. Nod2 consists 
of two amino-terminal caspase-recruitment domains (CARDs), 
a central self-oligomerization NACHT region and multiple carboxy-
terminal leucine-rich repeats11. Engagement of the leucine-rich 
repeats by MDP promotes a conformational change that exposes 
the NACHT domain, which allows self-oligomerization of Nod2 
and the binding of its CARDs to the CARD-containing kinase RIP2 
(refs. 12,13). RIP2 interacts with the kinase TAK1, which leads to 
activation of the transcription factor NF-κB and mitogen-activated 
protein kinases (MAPKs) and induction of the expression of proin-
flammatory cytokines14–18. Ubiquitination of RIP2 is critical for Nod2 
signaling pathways15,16.
The attachment of polyubiquitin chains to RIP2 serves to recruit 
TAK1 via the adaptors TAB2 and TAB3 (ref. 19), and that facili-
tates TAK1-induced phosphorylation and activation of IκB kinases 
(IKKs) that induce phosphorylation of inhibitory IκB proteins20. 
Phosphorylated IκB proteins undergo proteasome-mediated 
 degradation21 that allows NF-κB to translocate to the nucleus and 
induce proinflammatory gene expression22. Studies have investi-
gated the enzymes responsible for catalyzing the ubiquitination of 
RIP2. The Ubc13-Uev1a dimer acts as the E2 conjugating enzyme in 
the Lys63 (K63)-linked polyubiquitination of RIP2 (refs. 15,16), but 
the identity of the E3 ubiquitin ligase(s) that directly ubiquitinate(s) 
RIP2 to mediate Nod2-induced activation of NF-κB remains unclear. 
TRAF6 has been proposed as the main E3 ligase for RIP2 (ref. 15), but 
the ubiquitination of RIP2 is intact in TRAF6-deficient cells16 and 
knockdown of TRAF6 does not affect RIP2-mediated activation of NF-
κB9,14. Three members of the ‘IAP’ family of E3 ubiquitin ligases (XIAP, 
cIAP1 and cIAP2) have been proposed to regulate RIP2 ubiquitina-
tion23,24. Although the conclusions of the last two studies differ about 
the functional importance of cIAP1 and cIAP2 in mediating Nod2-
induced ubiquitination of RIP2, one demonstrated that XIAP promotes 
the ubiquitination of RIP2 and recruitment of the linear ubiquitin 
chain–assembly complex (LUBAC) to Nod2 (ref. 23). However, the 
XIAP-mediated polyubiquitination of RIP2 is not K63 linked, a type 
of linkage associated with RIP2-induced activation of NF-κB. The E3 
ligase Itch can also directly ubiquitinate RIP2 to negatively regulate 
Nod2-induced activation of NF-κB25. Thus, it remains unclear which 
E3 ubiquitin ligase directly catalyzes the K63-linked ubiquitination of 
RIP2 and mediates the Nod2-induced activation of NF-κB.
Pellino1, Pellino2 and two spliced forms of Pellino3 (Pellino3 long 
(Pellino3l; also called Pellino3a) and Pellino3 short (Pellino3s; also 
called Pellino3b)) constitute a family of E3 ubiquitin ligases26,27. 
They contain a phosphorylated threonine–binding amino-terminal 
forkhead-associated (FHA) domain and a carboxy-terminal RING-like 
domain that facilitate the recruitment and K63-linked polyubiquiti-
nation, respectively, of kinases of the IRAK family, which are signal-
ing intermediates in TLR pathways28–31. Pellino proteins undergo 
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Mutations that result in loss of function of Nod2, an intracellular receptor for bacterial peptidoglycan, are associated with Crohn’s 
disease. Here we found that the E3 ubiquitin ligase Pellino3 was an important mediator in the Nod2 signaling pathway. Pellino3-
deficient mice had less induction of cytokines after engagement of Nod2 and had exacerbated disease in various experimental 
models of colitis. Furthermore, expression of Pellino3 was lower in the colons of patients with Crohn’s disease. Pellino3 directly 
bound to the kinase RIP2 and catalyzed its ubiquitination. Loss of Pellino3 led to attenuation of Nod2-induced ubiquitination of 
RIP2 and less activation of the transcription factor NF-kB and mitogen-activated protein kinases (MAPKs). Our findings identify 
RIP2 as a substrate for Pellino3 and Pellino3 as an important mediator in the Nod2 pathway and regulator of intestinal inflammation.
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phosphorylation that regulates their E3 ligase activity31–35. Pellino1 
is a key mediator of NF-κB activation in the TLR3 and TLR4 signal-
ing pathways36 and is a negative regulator of T cell activation37,38. 
Pellino3 negatively regulates the TLR3-induced expression of type I 
interferons39. We identify Pellino3 here as an important mediator in 
the Nod2 pathway. We found lower expression of Pellino3 protein in 
the colons of patients with Crohn’s disease and diminished signaling 
pathways and colitis-protective effects of Nod2 in Pellino3-deficient 
mice. We propose that Pellino3 acts as a direct E3 ubiquitin ligase for 
RIP2 and thus facilitates the Nod2-mediated activation of NF-κB and 
downstream gene expression.
RESULTS
Pellino3 deficiency diminishes Nod2 signaling
We studied Pellino3-deficient (Peli3−/−) mice39 to assess the role 
of Pellino3 in activation of the Nod2 pathway. We obtained bone 
marrow–derived macrophages (BMDMs) from wild-type, Peli3−/− 
and Nod2-deficient (Nod2−/−) mice and compared their respon-
siveness to the Nod2 ligand MDP. Treatment of wild-type BMDMs 
with MDP resulted in higher expression of interleukin (IL-6), 
IL-1β, tumor-necrosis factor (TNF), the p40 subunit of IL-12 
(IL-12p40) and the chemokine CXCL1, but such induction was absent 
in Nod2−/− BMDMs and much lower in Peli3−/− BMDMs (Fig. 1a). 
MDP-induced expression of the mRNA encoding those cytokines 
was also absent from Nod2−/− BMDMs and was greatly diminished 
in Peli3−/− BMDMs (Fig. 1b). We next assessed the effect of Pellino3 
deficiency on the ability of Nod2 to act together with TLRs. Using 
expression of mRNA encoding IL-12p40 as a ‘readout’, we found that 
MDP enhanced the effects of the TLR4 ligand lipopolysaccharide 
(LPS) and the TLR2 ligand Pam3CSK4 in wild-type BMDMs but not 
in Peli3−/− BMDMs (Fig. 1c). Nod2 promoted the time-dependent 
activation of NF-κB and the three MAPK pathways (Jnk, p38 and Erk) 
in wild-type BMDMs, as indicated by the MDP-induced phosphoryla-
tion of IκBα and of Jnk, p38 and Erk, respectively, whereas the activa-
tion of all four pathways was lower in Peli3−/− BMDMs (Fig. 1d). We 
next addressed the role of Pellino3 as a mediator of the Nod2 path-
way in human cells. An NF-κB-regulated luciferase reporter gene was 
induced by expression of Nod2 in HEK293T human embryonic kidney 
cells transfected with control small interfering RNA (siRNA), whereas 
transfection with Pellino3-specific siRNA diminished the reporter 
activity (Supplementary Fig. 1a,b). Coexpression of either Pellino3s 
(Supplementary Fig. 1c) or Pellino3l (Supplementary Fig. 1d) 
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Figure 1 Pellino3 deficiency diminishes MDP-induced  
expression of proinflammatory cytokines in BMDMs.  
(a) Enzyme-linked immunosorbent assay (ELISA) of  
IL-6, IL-1β, TNF, IL-12p40 and CXCL1 in medium  
from wild-type (WT), Peli3−/− and Nod2−/− BMDMs  
left unstimulated (Ctrl) or treated with MDP  
(50 µg/ml) for 24 h. (b) Quantitative PCR analysis  
of Il6, Il1b, Tnf, Il12b and Cxcl1 mRNA in wild-type,  
Peli3−/− and Nod2−/− BMDMs left unstimulated or  
treated with MDP (50 µg/ml) for 3 h; results are  
presented relative to those of unstimulated wild-type  
BMDMs, set as 1. (c) Quantitative PCR analysis of  
mRNA encoding IL-12p40 (IL12b mRNA) in wild-type  
and Peli3−/− BMDMs left unstimulated or treated for  
2 h with LPS (1 µg/ml; top) or for 5 h with Pam3CSK4  
(1 µg/ml; bottom) in the presence (+MDP) or absence  
of MDP (10 µg/ml). (d) Immunoblot analysis of  
phosphorylated (p-) and total IκBα, p38, Jnk and Erk  
in lysates of wild-type and Peli3−/− BMDMs stimulated  
for 0–120 min (above lanes) with MDP (50 µg/ml);  
β-actin serves as a loading control throughout. NS, not significant; *P < 0.05, **P < 0.01 and ***P < 0.001 (two-tailed Student’s t-test). Data are from 
three independent experiments (mean and s.e.m. in a–c).
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enhanced Nod2-mediated activation of NF-κB in HEK292T cells. 
These results indicated a mediatory role for Pellino3 in the Nod2 
pathway in both mice and humans.
Because Nod2 is expressed in intestinal epithelial cells as well as 
myelomonocytic cells, we assessed the role of Pellino3 as a mediator 
of Nod2 signaling in the intestine. MDP-induced expression of the 
proinflammatory cytokines IL-6, CXCL1 and CCL2 was much lower 
in colon explants from Peli3−/− mice than in their wild-type counter-
parts (Supplementary Fig. 2a). In addition, MDP-induced cytokine 
expression and phosphorylation of IκBα, p38 and Jnk was lower in 
primary intestinal epithelial cells from Peli3−/− mice than in their wild-
type counterparts (Supplementary Fig. 2b, c). The siRNA-mediated 
suppression of Pellino3 in the human colonic epithelial cell line 
HCT116 diminished the ability of MDP to induce the cytokines IL-8, 
CXCL1 and TNF (Supplementary Fig. 2d) and resulted in much less 
MDP-induced phosphorylation of IκBα, p38 and Jnk (Supplementary 
Fig. 2e), which indicated that Pellino3 mediated Nod2 signaling in 
intestinal epithelial cells.
Given that Nod1 triggered those pathways similarly, we assessed the 
role of Pellino3 in Nod1 signaling in macrophages and epithelial cells. 
Suppression of Pellino3 expression by short hairpin RNA (shRNA) 
in the human monocytic cell line THP-1 inhibited the ability of the 
Nod1 ligand diaminopimelic acid to trigger phosphorylation of IκBα, 
p38 and Jnk (Supplementary Fig. 3a) and to induce IL-8, CXCL1 
and TNF (Supplementary Fig. 3b). Similarly, the shRNA-mediated 
decrease in Pellino3 expression in the human colonic epithelial cell 
line HT29 suppressed the diaminopimelic acid–induced activation of 
the NF-κB and MAPK pathways (Supplementary Fig. 3c) and induc-
tion of the proinflammatory cytokines noted above (Supplementary 
Fig. 3d), which indicated that Pellino3 also mediated Nod1 signaling 
in myelomonocytic cells and intestinal epithelial cells.
Intraperitoneal injection of MDP resulted in higher concentrations 
of IL-6, CXCL1, IL-12p40, IL-1β, IL-10 and TNF in serum from wild-
type mice (Fig. 2). Peli3−/− mice had basal serum concentrations of 
cytokines similar to those of their wild-type counterparts, but the 
MDP-induced increase in serum cytokines was significantly dimin-
ished. Together these results suggested that Pellino3 was a mediator in 
the Nod pathway in myelomonocytic and intestinal epithelial cells.
Pellino3 deficiency impairs clearance of Citrobacter rodentium
The regulatory function of Nod2 in intestinal homeostasis3 prompted 
us to evaluate the in vivo role of Pellino3 in controlling inflammation 
of the intestine. In a model of colitis induced by Citrobacter roden-
tium, in which Nod2 is central for bacterial clearance40, oral gavage 
with a bioluminescent bacteria resulted in an early peak of bacterial 
colonization at day 6 after infection in Peli3−/− mice, whereas wild-
type mice reached a peak of infection at day 9 after infection (Fig. 3a). 
Peli3−/− mice sustained a high fecal bacterial load from day 6 until 
day 16 after infection, whereas the peak bacterial load fell sharply 
in wild-type mice, which resulted in higher fecal bacterial loads in 
Peli3−/− mice than in wild-type mice at days 12 and 13 after infec-
tion. Live bioluminescence imaging showed a slightly more intense 
signal in the lower abdomen of infected Peli3−/− mice than in that 
of infected wild-type mice (data not shown), a result we confirmed 
by the significantly higher bioluminescent signal in infected Peli3−/− 
colons than in wild-type colons at day 12 after infection (Fig. 3b). 
Peli3−/− mice had a higher fecal bacterial load on day 19 than did 
wild-type mice (Fig. 3a), which suggested a delay in bacterial clear-
ance. After infection, C. rodentium did not spread to other mucosal or 
systemic organs in wild-type or Peli3−/− mice. As reported before40,41, 
we found that infected wild-type mice had significantly greater 
colon weight and shorter colons at day 12 after infection than before 
infection (Fig. 3c). Despite their higher bacterial load at that time 
point, infected Peli3−/− mice did not develop those signs of inflam-
mation (Fig. 3a,c). The histological scores of distal colons at day 12 
after infection indicated that Peli3−/− mice had less mucosal thicken-
ing (leukocyte infiltration), shorter colonic crypts (Fig. 3d) and less 
goblet-cell depletion (Fig. 3e) than did their wild-type counterparts. 
Analysis of proinflammatory cytokines in distal colon homogenates 
showed less IL-1β, CCL2, IL-6 and CXCL1 in Peli3−/− mice than in 
wild-type mice on day 12 after infection (Fig. 3f). We found no major 
difference between the two groups in the concentration of TNF, IL-10, 
IL-12p70 or interferon-γ (IFN-γ). Phenotyping of cells of the immune 
system from isolated mesenteric lymph nodes showed that Peli3−/− 
mice had a significantly fewer monocytes (CD11b+F4/80+Gr-1+), 
CD3+CD4+IL-17+ T cells and CD4+IFN-γ+ T cells than did wild-
type mice at day 12 after infection (Fig. 3g). However, in correlation 
with the greater fecal bacterial loads of Peli3−/− mice at later time 
points during infection, on day 21 after infection, the distal colons 
of Peli3−/− mice had a higher histological inflammatory score and 
a higher score for staining with periodic acid Schiff than did those 
of wild-type mice (Fig. 3e,h), which suggested a delay in the recov-
ery of goblet cells and mucus production in Peli3−/− mice. Thus, loss 
of Pellino3 resulted in less early inflammation and impaired clear-
ance of C. rodentium. Because Nod2 mediates intestinal clearance of 
C. rodentium by promoting the production of inflammatory cytokines, 
the recruitment of monocytes and enhanced responses of the TH1 and 
TH17 subsets of helper T cells in the intestine40, these findings were 
consistent with a role for Pellino3 in mediating the protective effects 
of Nod2 in this infection model.
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Figure 2 Peli3−/− mice have less induction of the expression of 
proinflammatory cytokines in response to MDP. Immunoassay of 
the expression of IL-6, CXCL1, IL-12p40, IL-1β, IL-10 and TNF in 
serum from wild-type and Peli3−/− mice (n = 6 per group) 4 h after 
intraperitoneal injection of MDP (25 mg per kg body weight) or endotoxin-
free PBS. Each symbol represents an individual mouse; small horizontal 
lines indicate the mean (and s.e.m.). *P < 0.05, **P < 0.01 and  
***P < 0.001 (two-tailed Student’s t-test). Data are from three 
independent experiments.
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Pellino3 is protective in chemically induced models of colitis
We next assessed whether Pellino3 was protective in two chemically 
induced models of colitis (induction with dextran sodium sulfate 
(DSS) or 2,4,6-trinitro benzene sulfonic acid (TNBS)) in which Nod2 
has a demonstrated protective role42. We provided mice with 2.5% 
DSS in the drinking water for 5 d and injected them intraperitoneally 
with MDP or endotoxin-free PBS on days 0, 1 and 2 and monitored 
their morbidity and body weight each day. DSS-treated wild-type 
mice developed progressive weight loss starting at day 4, whereas 
the administration of MDP diminished the severity of the weight 
loss (Supplementary Fig. 4a). As reported before42, the DSS-induced 
weight loss was not ameliorated by the administration of MDP to 
Nod2−/− mice (Supplementary Fig. 4a). DSS-treated Peli3−/− mice 
developed weight loss similar to that of wild-type mice, but adminis-
tration of MDP did not ameliorate this. Treatment with MDP resulted 
in less DSS-induced colon shortening in wild-type mice but not in 
Nod2−/− or Peli3−/− mice (Supplementary Fig. 4b). Histological anal-
ysis of sections of distal colons from untreated wild-type and Peli3−/− 
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Figure 3 Peli3−/− mice have impaired clearance of C. rodentium and less colonic inflammation. (a) C. rodentium in feces of wild-type and Peli3−/− mice 
(n = 8–17 per time point) on days 0–19 (horizontal axis) after infection with C. rodentium, presented as log10 colony-forming units (CFU) per gram 
feces. (b) Bioluminescent images (left) of the colon and cecum of uninfected (UI) and C. rodentium–infected wild-type and Peli3−/− mice (n = 8–9 per 
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sections (right; n = 3–4 mice per group (uninfected) or 8–9 mice per group (infected)). Arrows (left) indicate differences in mucin staining in goblet cells. 
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from uninfected and C. rodentium–infected wild-type and Peli3−/− mice (n = 3–4 per group (uninfected) or 7–9 per group (infected)) on day 12 after 
infection. Each symbol represents an individual mouse; small horizontal lines indicate the mean (and s.e.m.). (h) Histological inflammatory scores of 
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day 21 after infection. ND, not detected. *P < 0.05, **P < 0.01 and ***P < 0.001 (Mann-Whitney U-test (a,b), one-way analysis of variance followed by 
Bonferroni’s multiple-comparison test (c–f,h) or unpaired t-test with Welch’s correction (g)). Data are from one experiment.
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mice showed an intact intestinal epithelium (Supplementary Fig. 4c). 
After treatment with DSS, the distal colons of wild-type mice had 
considerable infiltration of inflammatory cells, severe lesions of the 
intestinal epithelium and loss of goblet cells, which was ameliorated 
by the administration of MDP (Supplementary Fig. 4c). In contrast, 
DSS-treated Peli3−/− mice were not protected from colitis pathology 
after administration of MDP (Supplementary Fig. 4d). These results 
were consistent with loss of the protective effects of MDP on colitis 
severity in Nod2−/− and Peli3−/− mice. In the TNBS-induced model, 
Peli3−/− mice developed greater weight loss, more colon shortening, 
greater exacerbation of tissue damage and worse overall pathology 
than did their wild-type littermates in response to the administration 
of TNBS (Supplementary Fig. 5a–d). These results indicated a role 
for Pellino3 in intestinal homeostasis and in mediating the protective 
effects of Nod2 in colitis.
Pellino3 interacts with RIP2
To probe the mechanistic basis of the mediatory role of Pellino3 
in the Nod2 pathway, we initially assessed the ability of Pellino3 to 
interact with RIP2. RIP2 immunoprecipitated together with both 
Pellino3s and Pellino3l in HEK293 cells coexpressing RIP2 and either 
spliced form of Pellino3 (Fig. 4a). RIP2 did not immunoprecipitate 
together with mutant forms of Pellino3s or Pellino3l with a nonfunc-
tional FHA domain, whereas alteration of the Pellino3 RING-like 
domain had no effect on the Pellino3-RIP2 interaction (Fig. 4a). 
Purified recombinant Pellino3s and Pellino3l, as well as the mutant 
forms with an altered RING-like domain, immunoprecipitated 
together with RIP2 from cell lysates, but the mutant forms with a 
nonfunctional FHA domain did not (Fig. 4b,c). Furthermore, puri-
fied recombinant Pellino3s and Pellino3s with an altered RING-like 
domain immunoprecipitated abundantly together with purified RIP2, 
but Pellino3s with a nonfunctional FHA domain did not (Fig. 4d). 
Finally, stimulation of Nod2 signaling in HEK293T cells by MDP 
promoted a time-dependent interaction beween endogenous Pellino3 
and RIP2 (Fig. 4e). These results indicated that Pellino3 directly 
interacted with RIP2 via its FHA domain.
Pellino3 ubiquitinates RIP2
We next assessed the ability of Pellino3 to regulate the ubiquitina-
tion of RIP2. Overexpression of Pellino3s or Pellino3l with RIP2 
in HEK293 cells resulted in substantial polyubiquitination of RIP2 
(Fig. 5a). Coexpression of A20, an enzyme known to counter-regulate 
Nod2 signaling by deubiquitinating RIP2 (ref. 43), abrogated the 
Pellino3-mediated ubiquitination of RIP2 (Fig. 5a). Because RIP2-
mediated signaling is dependent on modification with K63-linked 
polyubiquitin chains, we assessed the type of linkage induced by 
Pellino3 in the polyubiquitination of RIP2. We expressed Pellino3 with 
RIP2 and various forms of ubiquitin, ranging from wild-type ubiquitin 
containing all seven of its lysine residues to mutants lacking all lysine 
residues or containing a single lysine at various positions (Fig. 5b). 
Pellino3s promoted ubiquitination of RIP2 when coexpressed with 
wild-type ubiquitin or mutant ubiquitin with a single lysine at posi-
tion 63. With that ubiquitin mutant, wild-type Pellino3s and Pellino3l 
were equally able to promote K63-linked polyubiquitination of RIP2, 
whereas Pellino3s and Pellino3l mutants with alteration of the RING 
domain or FHA domain were totally ineffective (Fig. 5c). Wild-type 
Pellino3s and Pellino3l and their mutants with alteration of the RING 
domain or FHA domain did not ubiquitinate RIP2 when coexpressed 
with ubiquitin with a single point substitution of arginine for lysine 
at position 63 (K63R ubiquitin; Fig. 5d), whereas wild-type Pellino3s 
and Pellino3l promoted ubiquitination of RIP2 when expressed with 
K48R ubiquitin, but the mutant forms of Pellino3s and Pellino3l did 
not (Fig. 5e). This showed that Pellino3 ubiquitinated RIP2 exclu-
sively via K63 linkages.
We next used an in vitro ubiquitination assay with purified 
Pellino3s and recombinant RIP2 to assess whether Pellino3 directly 
ubiquitinated RIP2. Pellino3 catalyzed polyubiquitination of RIP2 
in the presence of recombinant mutant ubiquitin with a single lysine 
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Figure 4 Pellino3 interacts directly with RIP2 in a FHA domain–dependent manner. (a) Immunoassay of RIP2 and Pellino3 in HEK293T cells 
transfected with constructs encoding Flag-tagged RIP2 (Flag-RIP2 +) alone (−) or with Myc-tagged (Pellino-Myc) Pellino3s (3s) or Pellino3l (3l) or the 
corresponding mutants with a nonfunctional FHA domain (3sFm or 3lFm) or an altered RING domain (3sRm or 3lRm), followed by immunoprecipitation 
(IP) with antibody to Myc (anti-Myc) and immunoblot analysis (IB), with anti-Flag (RIP2) or anti-Myc (Pellino3), of immunoprecipitates or of lysates 
without immunoprecipitation (Input). (b,c) Immunoassay of RIP2 and Pellino3 in HEK293T cells transfected with a construct encoding Flag-tagged 
RIP2 and incubated alone (−) or with Myc-tagged purified recombinant forms (as in a) of Pellino3s (b) or Pellino3l (c), followed by immunoprecipitation 
with anti-Myc and immunoblot analysis of immunoprecipitates (left and middle) or of input without immunoprecipitation (I; far right). (d) Immunoblot 
analysis of RIP2 and Pellino among proteins precipitated with nickel agarose (His ppt) from samples of purified recombinant RIP2 incubated alone (−) 
or in the presence of purified recombinant forms (as in a) of Myc- and histidine-tagged Pellino3s, or of input without precipitation (I). (e) Immunoassay 
of Pellino3 and RIP2 in HEK293T cells transfected with an expression plasmid encoding Nod2 and then stimulated for 0–70 min (above lanes) with 
MDP (50 µg/ml), followed by immunoprecipitation with anti-RIP2 or isotype-matched control antibody (immunoglobulin G (IgG); far right (C)) and 
immunoblot analysis of immunoprecipitates or lysates with anti-Pellino3 or anti-RIP2. Arrows indicate the migration of Pellino3, RIP2 and the IgG 
heavy chain (IgGH). Data are representative of three experiments.
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at position 63 but not in the presence of K63R ubiquitin (Fig. 5f). 
Alterations in the RING and FHA domains of Pellino3 abrogated 
the in vitro ubiquitination of RIP2. Pellino3s with a nonfunctional 
FHA domain retained its E3 ligase catalytic activity, as it induced the 
formation of unanchored polyubiquitin chains, but it was unable to 
ubiquitinate RIP2, probably because of its inability to interact with 
RIP2 (Fig. 5f).
We next probed the structural features of RIP2 that facilitated 
the Pellino3-RIP2 association. RIP2 has an amino-terminal kinase 
domain and a carboxy-terminal CARD that are linked by an interme-
diate domain (Supplementary Fig. 6a). A truncated form of RIP2 that 
still contained the kinase domain immunoprecipitated with Pellino3 
(Supplementary Fig. 6b), whereas the intermediate domain and 
CARD were insufficient for binding to Pellino3 (Supplementary 
Fig. 6b,c). However, the kinase activity of RIP2 was not required for its 
interaction with Pellino3 or ubiquitination, as a kinase-inactive form 
of RIP2 (with substitution of arginine for the lysine at position 47)44 
interacted with Pellino3 and was ubiquitinated to the same extent as 
wild-type RIP2 (Supplementary Fig. 6d,e). Because ubiquitination 
of RIP2 at Lys209, in its kinase domain, is important for downstream 
activation of NF-κB16, we assessed if Pellino3 promoted ubiquitination 
of RIP2 at Lys209. A mutant form of RIP2 with substitution of 
arginine for the lysine at position 209 immunoprecipitated together 
with Pellino3 and still underwent Pellino3-mediated ubiquitination 
by K63-linked polyubiquitin chains (Supplementary Fig. 6f,g). Thus 
Pellino3 promoted K63-linked polyubiquitination of RIP2, at a site 
(or sites) other than Lys209, and in an FHA- and RING-like domain-
dependent manner.
Pellino3 mediates Nod2-induced polyubiquitination of RIP2
We next assessed the physiological relevance of the Pellino3-mediated 
polyubiquitination of RIP2 in the Nod2 pathway. MDP stimulated the 
polyubiquitination of endogenous RIP2 in a time-dependent manner 
in wild-type BMDMs, but this was much lower in Peli3−/− BMDMs 
(Fig. 6a). Through the use of antibodies that selectively recognize 
K63-linked or K48-linked polyubiquitin chains, we found MDP-
induced K63 polyubiquitination of endogenous RIP2 in wild-type 
BMDMs (Fig. 6a,b). MDP did not promote detectable K63-linked 
ubiquitination of RIP2 in Peli3−/− BMDMs.
Because K63-linked ubiquitination of RIP2 is associated with 
corecruitment of the TAK1 and IKK complexes into close proximity, 
which leads to downstream activation of NF-κB, we assessed the 
effects of Pellino3 deficiency on the Nod2-induced interaction 
of RIP2 with TAK1 and IKK. MDP promoted substantial and 
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Figure 5 Pellino3 catalyzes K63-linked polyubiquitination of RIP2. (a–e) Immunoassay of ubiquitin, RIP2 and Pellino3 in HEK293T cells transfected 
with constructs encoding various combinations (above lanes) of Flag-tagged RIP2 (a–e) and Myc-tagged Pellino3s or Pellino3l, Flag-tagged A20  
(Flag-A20) and hemagglutinin (HA)-tagged wild-type ubiquitin (HA-Ub) (a), Myc-tagged Pellino3s and HA-tagged wild-type ubiquitin or mutant 
ubiquitin lacking all seven lysine residues (K0) or with substitution of alanine for all lysine residues except the residue noted (K6, K11, K27, K29, K33, 
K48, K63) (b), HA-tagged mutant ubiquitin with substitution of alanine for all lysine residues except K63 (HA-Ub(K63)) and Myc-tagged Pellino3s or 
Pellino3l (wild-type and mutants as in Fig. 4a) (c), HA-tagged mutant ubiquitin with the K63R substitution (HA-Ub(K63R)) and Myc-tagged Pellino3s 
or Pellino3l as in c (d) or HA-tagged ubiquitin with the K48R substitution (HA-Ub(K48R)) and Myc-tagged Pellino3s or Pellino3l as in c (e), followed 
by immunoprecipitation with anti-RIP2 and immunoblot analysis of immunoprecipitates or lysates with anti-HA, anti-RIP2 or anti-Myc. (f) In vitro 
ubiquitination assay of E1 (100 nM), UbcH13-Uev1a (E2; 500 nM), purified recombinant RIP2 (400 ng) and ubiquitin (4 µg) with a single lysine at 
position 63 (left) or with the K63R substitution (right), in the presence (+) or absence (−) of recombinant forms (as in c) of Myc-tagged Pellino3s  
(0.5 µg), followed by immunoprecipitation with anti-RIP2 and immunoblot analysis of immunoprecipitates or lysates with anti-ubiquitin (Ub), anti-RIP2 
or anti-Myc. Data are representative of three independent expertiments.
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time-dependent recruitment of TAK1 and IKKγ (NEMO) to RIP2 in 
wild-type BMDMs, but this was abrogated in Peli3−/− BMDMs (Fig. 6c). 
However, published reports have indicated that IAP proteins regulate 
the Nod2-induced ubiquitination of RIP2 (refs. 23,24). To assess the 
relative importance of Pellino3 and the IAP proteins in this pathway 
and their potential functional interaction, we stimulated BMDMs from 
wild-type and Peli3−/− mice with MDP in the presence or absence of the 
IAP antagonist BV6, which pharmacologically depletes cells of cIAP1 
and cIAP2. Treatment of wild-type cells with BV6 did not affect the 
ability of MDP to promote the K63-linked ubiquitination of RIP2 or 
downstream phosphorylation of IκBα and p38 (Fig. 6d). The MDP-
induced ubiquitination of RIP2 and phosphorylation of IκBα and p38 
were substantially compromised in Peli3−/− BMDMs, and these effects 
were not further regulated by the addition of BV6 (Fig. 6d).
Because BV6 does not affect the expression of XIAP, we repeated the 
experiments described above with AT406, a compound that depletes 
cells of cIAP1 and cIAP2 and results in less XIAP in BMDMs. AT406 
partially diminished the MDP-induced total ubiquitination of RIP2 
in wild-type BMDMs, especially at later time points, but did not affect 
the MDP-induced K63-linked ubiquitination of RIP2 (Fig. 6e). AT406 
also had a slight inhibitory effect on the MDP-induced phosphor-
ylation of IκBα and p38 in wild-type BMDMs, which was weaker 
than the effects of Pellino3 deficiency in Peli3−/− BMDMs (Fig. 6e). 
However, treatment of Peli3−/− BMDMs with AT406 further aug-
mented the inhibitory effects associated with Pellino3 deficiency 
(Fig. 6e), which suggested that Pellino3 and XIAP may work in par-
allel. Because XIAP functions in Nod2 signaling by promoting recruit-
ment of the LUBAC23, we investigated the MDP-induced recruitment 
of the LUBAC component Sharpin to RIP2 in wild-type and Peli3−/− 
BMDMs. MDP promoted strong and time-dependent interaction of 
Sharpin with RIP2 in wild-type BMDMs, and this interaction was 
preserved in Peli3−/− cells (Fig. 6c). These data suggested a critical 
role for Pellino3 in the Nod2-induced K63-linked ubiquitination of 
RIP2 and recruitment of TAK1 and IKK complexes. Our results also 
suggested that XIAP worked in parallel with Pellino3 and were con-
sistent with a published report demonstrating that XIAP promotes 
ubiquitination of RIP2, in a non K63-linked manner, which leads to 
the recruitment of the LUBAC and downstream signaling23. Whereas 
Pellino3 and XIAP seemed to act in parallel and independently of each 
other, they both fed into the same downstream pathways, given the 
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Figure 6 Pellino3 mediates MDP- 
induced K63-linked polyubiquitination  
of RIP2 and downstream signaling  
in an IAP-independent manner.  
(a–c) Immunoassay of wild-type  
and Peli3−/− BMDMs stimulated  
for 0–70 min (above lanes) with  
MDP (50 µg/ml), followed by  
immunoprecipitation with anti-RIP2  
and immunoblot analysis of  
immunoprecipitates or lysates with  
anti-RIP2 (a–c) and antibody to  
ubiquitin (Ub) or to K63-linked  
ubiquitin (K63Ub) (a), antibody  
to K48-linked ubiquitin (K48Ub)  
(b) or anti-TAK1, anti-IKKγ and  
anti-Sharpin (c). (d,e) Immunoassay  
of wild-type and Peli3−/− BMDMs  
given no pretreatment (−) or  
pretreated (+) for 30 min with BV6 
(20 µM) (d) or for 1 h with AT406  
(30 µM) (e) and then stimulated for  
0–70 min (above lanes) with MDP (50 µg/ml), followed by immunoprecipitation with anti-RIP2 and immunoblot analysis of immunoprecipitates with 
antibody to ubiquitin or to K63-linked ubiquitin and anti-RIP2 and immunoblot analysis of lysates with antibody to all cIAP proteins (Pan-cIAP),  
anti-XIAP, anti-RIP2 and antibodies to phosphorylated (p-) and total IκBα and p38. Right margin (c), molecular size in kilodaltons (kDa); arrows  
(right margins, a–e) indicate the migration of RIP2 and the IgG heavy chain (IgGH). Data are representative of three independent experiments.np
g
© 
20
13
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
934  VOLUME 14 NUMBER 9 SEPTEMBER 2013 nature immunology
A rt i c l e s
additive nature of the inhibitory effects of the XIAP inhibitor AT406 
and Pellino3 deficiency on Nod2 signaling.
Nod2 depends on Pellino3 FHA and RING-like domains
We next sought to probe the functional relevance of the Pellino3- 
mediated K63-ubiquitination of RIP2 for downstream signaling in the 
Nod2 pathway. The deficiency in MDP-induced K63-polyubiquitination 
of RIP2 in Nod2-expressing Peli3−/− mouse embryonic fibroblasts 
(MEFs) was ‘rescued’ by reconstitution with wild-type mouse Pellino3, 
but Pellino3 with an altered RING-like domain or a nonfunctional 
FHA domain did not ‘rescue’ that deficiency (Fig. 7a). The loss of 
MDP-induced phosphorylation of IκBα and of p38, Jnk and Erk in 
Peli3−/− MEFs (relative to that in wild-type MEFs) was ‘rescued’ by 
the reintroduction of wild-type mouse Pellino3, but not by either 
of the mutant forms (Fig. 7b). The loss of MDP-induced activation 
of NF-κB in Peli3−/− MEFs, as measured by the induction of an 
NF-κB-regulated luciferase reporter gene, was ‘rescued’ by recon-
stitution with mouse Pellino3, but not by the Pellino3 mutants with 
alteration of the FHA or RING-like domain (Fig. 7c). Mouse Pellino3 
also restored the MDP-induced expression of the mRNA and protein 
products of the NF-κB-responsive genes Il6 and Tnf in Peli3−/− MEFs 
(Fig. 7d,e). The Pellino3 mutants with alteration of the FHA or RING-
like domain were ineffective (Fig. 7d,e). In addition, human Pellino3 
was able to reconstitute MDP-induced K63-linked ubiquitination 
of RIP2, downstream signaling and cytokine expression in THP-1 
cells in which Pellino3 expression was ablated by a Pellino3-specific 
shRNA construct, but Pellino3 mutants with alteration of the FHA 
or RING-like domain were ineffective (Supplementary Fig. 7a–c). 
These data indicated that Pellino3-mediated K63-linked ubiquitina-
tion of RIP2 was an important step in the Nod2 pathway that leads 
to downstream activation of NF-κB and induction of genes encoding 
proinflammatory molecules.
Lower expression of Pellino3 in Crohn’s disease
Because Pellino3 mediated the protective effects of Nod2 in experi-
mental colitis, we assessed Pellino3 expression in patients with 
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Figure 7 The FHA and RING domains of Pellino3 are both needed to mediate MDP-induced ubiquitination of RIP2 and downstream signaling.  
(a,b) Immunoassay of wild-type and Peli3−/− MEFs transfected with an expression construct for histidine-tagged Nod2 and empty vector (EV) or plasmid 
encoding Myc-tagged wild-type mouse Pellino3 (mPeli3) or mouse Pellino3 with a mutant FHA domain (mPeli3Fm) or RING domain (mPeli3Rm), 
left untreated or treated with MDP (50 µg/ml), followed by immunoprecipitation with anti-RIP2 and immunoblot analysis of immunoprecipitates with 
antibody to K63-linked ubiquitin and anti-RIP2 and immunoblot analysis of lysates with those antibodies plus anti-histidine (His) and anti-Myc (a),  
or immunoblot analysis of lysates with antibodies to phosphorylated (p-) and total IκBα, p38, Jnk and Erk, plus anti-histidine and anti-Myc (b).  
(c) NF-κB activity in wild-type and Peli3−/− MEFs transfected with an expression construct for Nod2 and with empty vector (EV) or plasmid encoding 
mouse Pellino3 (wild-type or mutant as in a,b), plus an NF-κB-regulated firefly luciferase construct, then left untreated or treated for 3 h with MDP 
(50 µg/ml), and assessed as firefly luciferase activity normalized to renilla luciferase activity and presented relative to that untreated wild-type cells 
transfected with empty vector, set as 1 (top), and immunoblot analysis of Nod2 and Pellino3 in those cells (bottom). (d,e) Quantitative PCR analysis of 
Il6 and Tnf mRNA (d) and ELISA of IL-6 and TNF (e) in wild-type and Peli3−/− MEFs transfected with an expression construct for Nod2 and with empty 
vector or plasmid encoding mouse Pellino3 (wild-type or mutant as in a,b), then left untreated or treated for 24 h with MDP (50 µg/ml); PCR results (d) 
are presented relative to those of untreated wild-type cells transfected with empty vector, set as 1. *P < 0.05, **P < 0.01 and ***P < 0.001 (two-tailed 
Student’s t-test). Data are from three independent experiments (mean and s.e.m. in c–e). 
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inflammatory bowel disease (IBD), such as Crohn’s disease and 
ulcerative colitis. We searched a publically available database of 
genome-wide association studies of IBD with the Broad Institute’s 
Ricopili tool for visualizing regions of interest but found no asso-
ciation of single-nucleotide polymorphisms of PELI3 with Crohn’s 
disease or ulcerative colitis. We then used immunoblot analysis to 
assess the expression of Pellino3 in colonic biopsy samples from 
healthy controls and patients with Crohn’s disease or ulcerative 
colitis. We consistently found much lower expression of Pellino3 
in samples from patients with Crohn’s disease than in those from 
control subjects or patients with ulcerative colitis (Fig. 8). There 
was no correlation between the expression of Nod2 or IAP in those 
samples and disease phenotype (Fig. 8). These data suggested that 
dysregulation of Pellino3 expression may be important in the patho-
genesis of Crohn’s disease.
DISCUSSION
Our study has identified Pellino3 as an important mediator of the 
Nod2 pathway and has extended the understanding of the physi-
ological role of Pellino proteins in the innate immune system. 
Ubiquitination of RIP2 via K63-linked polyubiquitin chains is a 
critical step in the Nod2 pathway. Many E2 enzymes (such as the 
heterodimeric complex Ubc13-Uev1a15) and E3 ubiquitin enzymes 
(cIAP1, cIAP2, xIAP, TRAF6 and Itch15,23–25,45) have been proposed 
to catalyze that critical ubiquitination step. Whereas cIAP1 can 
directly catalyze the attachment of various types of ubiquitin chains 
to RIP2 with the help of the E2 enzyme UbcH5a45, and knockdown 
of cIAP1 expression results in less ubiquitination of overexpressed 
RIP2 (ref. 24), pharmacological depletion of cIAP1 does not affect 
the MDP-induced ubiquitination of RIP2 in wild-type cells23. Here 
we also found that pharmacological depletion of cIAP1 and cIAP2 did 
not regulate the MDP-induced ubiquitination of RIP2 or downstream 
activation of NF-κB or MAPK pathways in wild-type BMDMs and 
that depletion of cIAP had no additional affect on Peli3−/− BMDMs. 
A published study has reported that XIAP serves a key role in Nod2 
signaling by promoting the ubiquitination of RIP2 and recruitment 
of the LUBAC to Nod2 (ref. 23). We found that depletion of XIAP 
augmented the inhibitory effects of Pellino3 deficiency on the Nod2-
mediated activation of NF-κB and p38, which suggested that Pellino3 
and XIAP may act in parallel to regulate Nod2 signaling. We propose 
a model in which Nod2-triggered K63-linked polyubiquitination of 
RIP2 is critically mediated by Pellino3 and leads to recruitment of the 
TAK1 and IKK complexes and ensuing downstream signaling. That is 
closely followed by XIAP-mediated ubiquitination of RIP2, in a non–
K63-linked manner, which leads to recruitment of the LUBAC and 
linear ubiquitination of signaling components that also feed positively 
into Nod2 downstream signaling. Such a model shares similarity with 
the TNF signaling pathway, in which early K63-linked ubiquitination 
of signaling molecules proximal to the TNF receptor is followed by 
LUBAC-catalyzed linear ubiquitination of components of the receptor 
complex, which results in stabilization of the signaling complexes and 
enhanced downstream signaling46.
Our study adds to an emerging paradigm in which Pellino pro-
teins target important signaling intermediates in immunological sig-
naling pathways. Our identification of RIP2 as an important target 
for Pellino3, coupled with a published report describing Pellino1 as 
the E3 ubiquitin ligase for RIP1 in the TLR3 and TLR4 pathways36, 
emphasizes notable molecular and functional relationships between 
the Pellino and RIP kinase families. Furthermore, given that Pellino 
proteins were initially characterized as interaction partners and E3 
ubiquitin ligases for IRAKs26 and that the latter have roles equiva-
lent to those of RIP kinases in regulating downstream signaling 
pathways,our study adds to the growing appreciation of the impor-
tance of the Pellino family in regulating, by ubiquitination, the func-
tion of kinases critically important to innate immunity.
Pellino3 deficiency led to exacerbation of pathology in three inde-
pendent models of experimental colitis demonstrated before to be 
mediated by Nod2. Like Nod2-deficient mice40, Peli3−/− mice had 
impaired clearance of C. rodentium associated with diminished early 
inflammatory and TH1 and TH17 responses and impairment in epi-
thelial and mucosal recovery and greater inflammation at the later 
stages of colitis. Such enhanced inflammation may mirror the inflam-
matory phenotype associated with loss-of-function mutations in Nod2 
and Crohn’s disease. We have also identified a role for Pellino3 in 
Nod1 signaling, and given that like Nod2, Nod1 has an important 
role in the response to infection with C. rodentium47, some of the 
in vivo effects of Pellino3 in this model may also be attributed to its 
regulation of the Nod1 pathway.
We also found substantial downregulation of Pellino3 expression 
in colon samples from patients with Crohn’s disease but not those 
from patients with ulcerative colitis, which possibly reflects the more 
selective role of the Nod2 pathway in the former pathology. Whereas 
mutations and polymorphisms in NOD2 represent the most frequent 
genetic associations with Crohn’s disease, most patients who develop 
Crohn’s disease have the wild-type form of this gene. In those cases, 
the genetic defects may lie in genes that encode signaling components 
Figure 8 Pellino3 expression is much lower in colons from patients with Crohn’s disease. Immunoblot analysis of Pellino3, Nod2, XIAP and cIAP1-
cIAP2 (Pan-cIAP) in samples from three independent cohorts (1–3) of male (M) and female (F) healthy control subjects (Ctrl; n = 11) and patients with 
established ulcerative colitis (UC; n = 5) or Crohn’s disease (CD; n = 14); second blot in each group, immunoblot analysis with antibody to Pellino3 
in the presence of the immunogenic peptide used to generate the anti-Pellino3 (to show immunoreactive bands due to nonspecific binding of anti-
Pellino3). Data are representative of three experiments (one per cohort).
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downstream of Nod2. Initial studies of existing data from genome-
wide association studies did not identify any mutations or polymor-
phisms in the gene encoding Pellino3, but this does not exclude the 
possibility that rare variants of PELI3 that are not captured by such 
studies may be a contributing factor. This should encourage future 
studies to expand the increasing appreciation of the importance of 
Pellino proteins in health and disease.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Cell culture. HEK293T and HT29 cells were cultured in Dulbecco’s modi-
fied Eagle’s medium. HCT116 cells were cultured in McCoy’s 5A medium 
plus GlutaMAX-I medium (Sigma). THP-1 cells were cultured in RPMI-1640 
medium plus GlutaMAX-I medium (Gibco). All growth medium was supple-
mented with 10% (vol/vol) FBS (Hyclone), penicillin (100 U/ml) and strepto-
mycin (100 µg/ml). For isolation of BMDMs, tibias and femurs were removed 
from wild-type and Peli3−/− mice by sterile techniques and the bone marrow 
was flushed with fresh RPMI medium. Cells were plated in medium supple-
mented with 10% (vol/vol) conditioned medium of L929 mouse fibroblasts 
and were maintained for 4–6 d at 37 °C in a humidified atmosphere of 5% CO2. 
For isolation of colonic epithelial cells, colons were excised from wild-type 
and Peli3−/− mice, washed briefly in PBS and then thoroughly flushed with 
Hank’s balanced-salt solution containing 1% (wt/vol) penicillin, 1% (wt/vol) 
streptomycin and gentamicin (25µg/ml). Colons were opened longitudinally, 
cut into small segments and washed extensively with Hank’s balanced-salt 
solution before being chopped into a homogenized paste. That paste was incu-
bated at 37 °C for 1 h in DMEM containing collagenase (150 U/ml), hyaluro-
nidase (150 µg/ml) and 1% (vol/vol) FBS and then was centrifuged at 1,000g 
for 5 min. Pellets were washed with DMEM containing 2% (wt/vol) sorbitol, 
and the supernatant containing the purified crypt fraction was collected and 
centrifuged at 400g for 5 min. Crypts were then resuspended in high-glucose 
DMEM containing 5% (vol/vol) FBS, 7.5% (wt/vol) sodium pyruvate and insu-
lin (0.25 U/ml) and were plated on collagen-coated plates. The medium was 
changed every 2 d and cells were allowed to grow to confluency before being 
treated. For the preparation of MEFs, Peli3+/– mice were bred to generate wild-
type and Peli3−/− embryos. Embryos were dissected from pregnant females 
at day 13 after mating. MEFs isolated by standard procedures were cultured 
in DMEM supplemented with 10% (vol/vol) FBS and containing penicillin 
(100U/ml) and streptomycin (100 µg/ml). All cell types were maintained in 
humidified atmosphere a 37 °C with 5% CO2.
Colon explants. Colons were excised from wild-type and Peli3−/− mice, washed 
briefly in PBS and then thoroughly flushed with PBS containing 1% (wt/vol) 
penicillin-streptomycin. Colons were opened longitudinally, cut into segments 
0.5 cm in length and washed extensively with PBS containing 1% (wt/vol) 
penicillin/streptomycin. Size- and weight-matched explant segments were 
placed in flat-bottomed 24-well plates in RPMI growth medium and treated.
Expression vectors. Plasmids encoding wild-type Pellino3s or Pellino3l tagged 
at the carboxy terminus with Myc (pcDNA3.1-Pellino3s-myc or pcDNA3.1-
Pellino 3l-myc) and similarly Myc-tagged mutants with a nonfunctional FHA 
domain (Pellino3s with substitution of alanine for arginine at position 131 
and for serine at position 161 (R131A-S161A) and Pellino3l with substitution 
of alanine for arginine at position 155 and for serine at position 185 (R155A-
S185A)) or an altered RING domain (Pellino3s with substitution of alanine 
for cysteine at positions 360 and 363 (C360A-C363A) and Pellino3l with sub-
stitution of alanine for cysteine at positions 384 and 387 C384A/C387A)) 
and A20 tagged with Flag at the carboxy terminus (A20-Flag) were generated 
in-house. Hemagglutinin-tagged wild-type ubiquitin and ubiquitin lacking 
all seven lysine residues or all lysine residues except K6, K11, K27, K29, K33, 
K48 or K63 were from Addgene. Flag-tagged RIP2 and Nod2 were from P.A. 
Barker and M. Saleh. Myc-tagged wild-type and mutant (as described above) 
Pellino3s and Pellino3l constructs were also subcloned into histidine-tagged 
pRSET-A (Invitrogen). Mouse Pellino3 from mouse embryo brain was cloned 
into the pcDNA3.1 vector. Mutants of mouse Pellino with a nonfunctional 
FHA domain (with substitution of alanine for serine at position 161 (S161A)) 
or an altered RING domain (with substitution of alanine for cysteine at posi-
tions 360 and 363 (C360A-C363A) were generated in-house. Glutathione 
S-transferase–tagged RIP2 (H00008767-P01) was from Novus.
Antibodies and reagents. Anti-IκBα (C-21; sc-371), anti-Ub (P4D1; sc-8017), 
anti-Tak1 (M-579; sc-7162), anti-IKKγ (FL-419; sc-8330) and anti-RIP2 
(H-300;sc-22763) were from Santa Cruz; anti-Myc (2276), antibody to phospho-
rylated IκBα (9246), anti-Jnk(9252), anti-p38 (9212), anti-Erk (9102), antibody 
to phosphorylated Jnk (9251), antibody to phosphorylated Erk (9101) and anti-
body to phosphorylated p38 (9211) were from Cell Signaling; anti-HA (16B12; 
MMS-101P) was from Covance; antibody to K63-linked ubiquitin (HWA4C4; 
BML-PW0600) was from Enzo Life Science; antibody to K48-linked ubiquitin 
(Apu2; 05-1307) was from Millipore; antibody to all mouse cIAP (MAB3400) 
and anti-XIAP (MAB822) were from R&D Systems; anti-Flag (F3165) and 
anti-β-actin (AC-15;A 1978) were from Sigma; polyclonal antibody to Sharpin 
(14626-1-AP) was from Proteintech; rabbit anti-Pellino3 was generated in-
house; IRDye 680RD–anti-mouse (926-68070) and IRDye 800CW–anti-rabbit 
(926-32211) were from LI-COR Biosciences; IRDye 800CW–anti-goat 
(605-731-002) was from Rockland; horseradish peroxidase–anti-mouse (115-
035-008) and horseradish peroxidase–anti-rabbit (211-032-171) were from 
Jackson ImmunoResearch; and fluorescein isothiocyanate–anti-CD4 (GK1.5), 
phycoerythrin–anti-CD11b (M1/70; 12-0112), allophycocyanin–anti-Gr-1 
(RB6-8C5; 17-5931-81) and allophycocyanin–anti-IFN-γ (XMG1.2; 17-7311) 
and the isotype-matched control antibodies phycoerythrin-conjugated rat IgG2b 
κ-chain (Eb149/10H5; 12-4031), allophycocyanin-conjugated rat IgG2b κ-chain 
(Eb149/10H5; 17-4031), allophycocyanin-conjugated rat IgG1 κ-chain (eBRG1; 
17-4301), phycoerythrin-conjugated rat IgG1 κ-chain (eBRG1; 12-4301) and 
fluorescein isothiocyanate–conjugated rat IgG2a κ-chain (eBR2a; 11-4321) 
were from eBioscience. Fluorescein isothiocyanate–anti-F4/80 (BM8; 123107) 
was from Biolegend. Allophycocyanin–anti-CD3 (145-2C11; 553066), 
phycoerythrin–anti-IL-17 (TC11-18H10; 559502) and allophycocyanin- 
conjugated Armenian hamster IgG1 κ-chain (isotype-matched control anti-
body; A19-3; 553974) were from Becton Dickenson. EasyBlocker and EasyBlot 
horseradish peroxidase–conjugated antibody to rabbit IgG (GTX221666-01) 
were from GeneTex; MDP (Ac-muramyl-Ala-d-Glu-NH2; G-1055) was from 
Bachem. MDP was transfected into cells through the use of Lipofectamine 
2000. Pellino3-specific siRNA (sense, 5′-GCACAGCAUCUCGUAUAC 
ATT-3′; antisense, 5′-UGUAUACGAGAUGCUGUGCTG3-′) was from 
Ambion and cells were transfected through the use of Lipfectamine 2000 
according to the manufacturer’s instructions (Invitrogen). LPS was from Enzo 
Life Sciences. Pam3CSK4 (tripalmitoyl cysteinyl seryl tetralysine lipopeptide) 
was from Invivogen.
Knockdown of Pellino3 by lentiviral shRNA in human cells. Lentiviral con-
structs encoding human Pellino3–specific shRNA specifically targeted the 
3′ untranslated region of PELI3 and had the following sequence: GCACTTG
CTGATAGCCACTATCCGGGCACTTGCTGATAGCCACTATCTCGAGAT
AGTGGCTATCAGCAAGTGCTTTTTTG. Constructs were transfected into 
HEK293T cells together with packaging and envelope plasmids (dR89.1 and 
VSV-G), and lentivirus from supernatants of the medium was used to infect 
THP-1 cells. Cells were then grown for 4 d under puromycin (10 µg/ml) selec-
tion. Knockdown efficiency was assessed by immunoblot analysis of Pellino3 
in whole-cell lysates. Control cells were infected with lentivirus containing a 
nontargeting vector that encodes shRNA that does not match the sequence 
of any known human or mouse gene. For rescue assays, Plv lentiviral vec-
tors encoding Myc-tagged wild-type or mutant Pellino3l were transfected 
into HEK293T cells along with packaging and envelope plasmids (pPTK and 
pMDG). Plv lentivirus from the medium supernatants was used for infection 
THP-1 cells along with shRNA lentivirus. Cells were grown for 4 d under 
puromycin (10µg/ml) selection before experiments.
Mice. Peli3−/− mice were generated on a C57BL/6J background as described39. 
Nod2−/− mice were generated on a C57BL/6J strain background, and wild-
type C57BL/6J mice originally from Jackson Laboratories were bred in-house. 
All animal experiments were done in accordance with the regulations and 
guidelines of the Irish Department of Health and protocols were approved 
by the Research Ethics committees of National University of Ireland 
Maynooth, Trinity College Dublin and the University College Cork Animal 
Experimentation Ethics Committee.
Chemically induced colitis models. Two mouse models of chemically induced 
intestinal inflammation were generated by the administration of DSS or TNBS. 
Colitis was induced by DSS as described48. DSS (35,000–50,000 kDa; MP 
Biomedicals) was dissolved in the drinking water provided to mice. Fresh 
DSS solution was provided every second day. Wild-type, Peli3−/− and Nod2−/− 
mice received 2.5% DSS for 5 d, followed by ‘normal’ drinking water (without 
DSS) for 3 d. On days 0, 1, and 2, mice were also given intraperitoneal injection 
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of either MDP (100µg per mouse) or endotoxin-free PBS. Colitis was induced 
by TNBS as described49. TNBS solution (100 µl volume; 3.75 mg per mouse in 
45% (vol/vol) ethanol) or vehicle control solution (45% ethanol) was admin-
istered into the colon lumen of anesthetized mice by insertion of a catheter 
4 cm proximal to the anus. After administration of DSS or TNBS, mice were 
checked each day for morbidity and body weight. At autopsy, the lengths of 
the colons were measured and a segment of distal colon ~1 cm in length was 
removed and fixed in 10% formaldehyde in saline. Tissue was embedded in 
paraffin and sections 5 µm in thickness were stained with hematoxylin and 
eosin. Histology scores were assigned by researchers ‘blinded’ to sample iden-
tity, according to the following scoring system: a maximum combined score of 
10 was obtained from the amount of inflammatory cell infiltration (0, none; 1, 
slightly dispersed cell infiltrate; 2, moderately increased cell infiltrates forming 
occasional cell foci; and 3, severely large areas of cell infiltrates causing loss 
of tissue architecture), extent of injury (0, none; 1, mucosal; 2, mucosal and 
submucosal; and 3, transmural), and crypt damage (0, none; 1, basal one-third 
damaged; 2, basal two-thirds damaged; 3, only surface epithelium intact; and 
4, loss of entire crypt and epithelium).
C. rodentium infection and bioluminescent imaging of mice. Mice were 
randomly separated into groups of eight to nine mice and were given 1 × 1010 
CFU of the bioluminescent C. rodentium derivative strain ICC180 by oral 
gavage and then were monitored for changes in body weight and clinical signs 
of disease as described41,50. Bacteria were counted in fecal samples collected 
at various time points and in homogenates of spleen, liver and mesenteric 
lymph nodes collected when mice were killed on days 12 and 21 after infec-
tion as described41,50. In vivo bioluminescence imaging of whole body and 
colons was done with an IVIS 100 charge-coupled-device imaging system 
(Xenogen). Bioluminescent signals were quantified for regions of interest over 
the same surface area of the whole body and colons. Background was omitted 
by the measurement of signal intensity in regions of interest of whole body and 
colons of uninfected mice and subtraction of that from the results obtained for 
infected mice. Imaging data were analyzed and quantified with Living Image 
software (version 2.50; Xenogen) and are presented as the number of photons 
per second per cm2.
After colons were imaged, the length and weight of colon was measured. The 
distal 3 cm were divided longitudinally. One piece was frozen in liquid nitrogen 
and later thawed, homogenized and analyzed with a Mouse ProInflammatory 
7-Plex Ultra-Sensitive kit (Meso Scale Discovery) to assess IFN-γ, TNF, IL-1β, 
IL-6, IL-10, IL-12p70 and keratinocyte chemoattractant and by ELISA (R&D 
Systems) to assess CCL2, each according to the manufacturer’s instructions. 
The other piece of distal colon was rolled (like a ‘Swiss roll’) and fixed in 10% 
formalin, followed by embedding in paraffin as described above.
Staining with hematoxylin and eosin and periodic acid Schiff stain. Sections 
of distal colon 5 µm in thickness were stained with hematoxylin and eosin or 
with periodic acid Schiff stain according to standard histological procedures. 
Each whole-colon ‘Swiss roll’ was evaluated by a researcher (S.M.) ‘blinded’ 
to sample identity, and scores were assigned on a scale of 0 to 3 (0, none; 1, 
mild; 2, moderate; 3, severe) for inflammatory damage, such as goblet cell 
loss, crypt elongation, mucosal thickening, and epithelial injury, including 
hyperplasia and shedding of enterocytes into the gut lumen; this yielded a 
maximum score of 12 per mouse section41. For mucin staining, a score based 
on the number and size of mucin-containing cells, on a scale of 0 to 3, was 
assigned as described above; this yielded a maximum score of 6 per section.
Flow cytometry. Mesenteric lymph nodes were dissected, homogenized in 
RPMI medium and centrifuged for 5 min at 1500g and 4 °C. Supernatants were 
discarded and red blood cells were lysed in 0.15 M NH4Cl, 1 mM KHCO3 and 
0.1 mM EDTA, pH 7.2, followed by dilution in RPMI medium and further cen-
trifugation as described above. Cell pellets were resuspended in RPMI medium 
(1 × 106 cells per ml). Aliquots of cell suspensions (200 µl in volume) were 
transferred to V-bottomed 96-well plates and stained with phycoerythrin–anti-
CD11b (M1/70; 12-0112; eBioscience), allophycocyanin–anti-Gr-1 (RB6-8C5; 
17-5931-81; eBioscience), fluorescein isothiocyanate–anti-F4/80 (BM8; 123107; 
Biolegend), allophycocyanin–anti-CD3 (145-2C11; 553066; BD) or fluorescein 
isothiocyanate–anti-CD4 (GK1.5; eBioscience), and expression was assessed 
by flow cytometry with an Accuri C6 (BD). Cells were also fixed and made 
permeable with a commercial kit (eBioscience) and intracellular cytokines were 
analyzed with allophycocyanin–anti-IFN-γ (XMG1.2; 17-7311; eBioscience) 
and phycoerythrin–anti-IL-17 (TC11-18H10; 559502; BD). Nonspecific stain-
ing was defined through the use of the following isotype-matched control anti-
bodies with the respective fluorochrome label: phycoerythrin-conjugated rat 
IgG2b κ-chain (Eb149/10H5;12-4031), allophycocyanin-conjugated rat IgG2b 
κ-chain (Eb149/10H5; 17-4031), allophycocyanin-conjugated rat IgG1 κ-chain 
(eBRG1; 17-4301), phycoerythrin-conjugated rat IgG1 κ-chain (eBRG1; 
12-4301) and fluorescein isothiocyanate–conjugated rat IgG2a κ-chain (eBR2a; 
11-4321; all from eBioscience); and allophycocyanin-conjugated Armenian 
hamster IgG1 κ-chain (A19-3; 553974; BD).
Luciferase reporter assay. HEK293T cells (1.2 × 105 cells per ml; 200 µl) and 
MEFs (0.8 × 105 cells per ml; 200 µl) were seeded in 96-well plates. Cells were 
cotransfected, through the use of Lipofectamine 2000 transfection reagent, 
with plasmids encoding NFκB-regulated firefly luciferase and thymidine 
kinase–controlled renilla luciferase (Promega Biosciences) and designated 
amounts of expression constructs encoding Nod2 and various forms of 
Pellino3. Cells were allowed to grow for another 24 h and then treated for 
18 h with MDP. Cell extracts were collected in Reporter Lysis Buffer (Promega 
Biosciences), and firefly and renilla luciferase activity was assayed with the 
Luciferase Assay system (Promega Biosciences) and coelenterazine (1 µg/ml, 
Insight Biotechnology), respectively. In some experiments, cells were initially 
transfected with siRNA 24 h before further transfection with the expression 
constructs described above.
Real-time PCR assays. Primary BMDMs (1.5 × 106 cells per ml; 2 ml) and MEFs 
(1.2 × 105 cells per ml; 2 ml) were seeded into 12-well plates. After the appro-
priate treatment(s), RNA was extracted with TRIzol (Invitrogen). Then, cDNA 
was generated from RNA (2 µg) with MMLV Reverse Transcriptase (Bioscript 
Bioline) and real-time PCR analyses were done with Brilliant SYBR Green QPCR 
Master mix according to the manufacturer’s instructions (Stratagene). The fol-
lowing primers were used: mouse Il6, forward, ACAACCACGGCCTTCCCTAC, 
and reverse, TCCACGATTTCCCAGAGAACA; mouse Il1b, forward, TTGAA 
GTTGACGGACCCCA, and reverse, ATGAGTGATACTGCCTGCCTGA; 
mouse Tnf, forward, CATCTTCTCAAAATTCGAGTGA, and reverse, TGG 
GAGTAGACAAGGTAC; mouse Il12b, forward, TGGTTTGCCATCGTTTT 
GC, and reverse, GGGAGTCCAGTCCACCTCTACA; and mouse Cxcl1, 
forward, CACCCAAACCGAAGTCATAGC, and reverse, TTGGGGACACC 
TTTTAGCATC. The abundance of each mRNA was normalized relative 
to PCR of the housekeeping gene Hprt with the following primers: 
forward, GTCCCAGCGTCGTGATTAGC, and reverse, TGGCCTCCCAT 
CTCCTTCA.
Cytokine ELISA. Primary BMDMs were seeded (1.5 × 106 cells per ml; 2ml) 
in 12-well plates and were allowed to grow for 24 h. Cells were then stimulated 
for 24 h with MDP (50 µg/ml). Conditioned medium was collected, and IL-1β, 
IL-6, TNF, IL12p40 and CXCL1 were measured by sandwich ELISA (R&D 
Systems). Colon explants and primary mouse colonic epithelial cells isolated 
from wild-type and Peli3−/− mice were left untreated or were stimulated for 16 h 
or 24 h with MDP (50 µg/ml). The medium was collected and IL-6, CXCL1 
and CCL2 proteins were analyzed. For MEFs, cells were seeded (1.2 × 105 
cells per ml; 2ml) in 12-well plates and were allowed to grow for 24 h. At 24 h 
after transfection, cells were treated for 18 h with MDP and then conditioned 
medium was collected for assay. HCT116, THP-1 and HT29 cells with and 
without (control) knockdown of Pellino3 were treated for 24 h with MDP 
(50 µg/ml) or diaminopimelic acid (50 µg/ml) and human IL-6, IL-8, TNF and 
CXCL1 (R&D Systems) were measured in the medium. For analysis of cytokine 
abundance in mice challenged with MDP, wild-type and Peli3−/− mice were 
given intraperitoneal injection of MDP (25 mg per kg body weight) and blood 
was collected 4 h after injection. IL-6, keratinocyte chemoattractant, IL-12p40, 
IL-1β, IL-10 and TNF were measured in the serum by the Multi-spot assay 
system, according to the manufacturer’s instructions (MSD).
Immunoprecipitation and immunoblot analysis. Primary BMDMs (2 × 106 cells 
per ml; 10 ml)and MEFs (2 × 105 cells per ml; 10 ml) were grown in 
np
g
© 
20
13
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
 nature immunologydoi:10.1038/ni.2669
10-cm dishes. Cells lines were grown in six-well plates and in some cases were 
transfected with the appropriate expression constructs. Cells were then col-
lected in 500 µl lysis buffer (20 mM Tris-HCl, pH 7.4, containing 150 mM 
NaCl, 1% (vol/vol) Igepal, 10% (wt/vol) glycerol, 50 mM NaF, 1 mM Na3VO4, 
1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and complete pro-
tease-inhibitor ‘cocktail’ (Roche)), followed by incubation for 30 min at 4 °C. 
Cell lysates were initially precleared with nonimmune IgG antibody (1 µg; 
mouse IgG control (sc-2025; Santa Cruz) or rabbit IgG control (sc-2027; Santa 
Cruz)) and protein A–protein G–agarose (10 µl) , followed by incubation for 
24 h at 4 °C with the appropriate antibody (2 µg each: anti-Myc (2276; Cell 
Signaling) or anti-RIP2 (H-300; sc-22763; Santa Cruz)). An aliquot (50 µl) of 
protein A–protein G–agarose was added to each sample, followed by incuba-
tion overnight at 4 °C. Immunoprecipitates were collected by centrifugation 
for 1 min at 1,000g and 4 °C and the beads were then washed four times with 
500 µl lysis buffer (without Na3VO4, dithiothreitol, phenylmethylsulfonyl flu-
oride or protease-inhibitor ‘cocktail’). An aliquot (50 µl) of SDS-PAGE sample 
buffer (62.5 mM Tris-HCl, pH 6.8, 10% (wt/vol) glycerol, 2% (wt/vol) SDS, 
0.7 M β-mercaptoethanol and 0.001% (wt/vol) bromophenol blue) was added 
to the beads. Samples were resolved by SDS-PAGE, transferred to nitrocellu-
lose membranes and analyzed by immunoblot with the appropriate antibodies 
as follows: anti-RIP2 (H-300; sc-22763; Santa Cruz), anti-Myc (2276; Cell 
Signaling), anti-ubiquitin (P4D1; sc-8017; Santa Cruz), anti-hemagglutinin 
(16B12; MMS-101P; Covance), anti-TAK1 (M-579; sc-7162; Santa Cruz), 
anti-IKKγ (FL-419; sc-8330; Santa Cruz), antibody to K63-linked ubiquitin 
(HWA4C4; BML-PW0600; Enzo Life Science), antibody to K48-linked ubiq-
uitin (Apu2; 05-1307; Millipore), polyclonal antibody to Sharpin (14626-1-AP; 
Proteintech) and anti-Pellino3 (generated in-house). Immunoreactivity was 
visualized by the Odyssey Imaging System (LI-COR Biosciences) or enhanced 
chemiluminescence. For experiments assesing the ubiquitination status of 
RIP2, cells were collected in 100 µl lysis buffer (20 mM Tris-HCl, pH 7.4, con-
taining 150 mM NaCl, 1% (vol/vol) Igepal, 10% (wt/vol) glycerol, 50 mM NaF, 
1 mM Na3VO4, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 
complete protease-inhibitor ‘cocktail’ (Roche)). Cell lysates were treated with 
1% (wt/vol) SDS and were heated to 95 °C for 5 min to dissociate RIP2 from 
any associated proteins. Lysates were then diluted tenfold in lysis buffer before 
immunoprecipitation and immunoblot analysis as described above.
Generation of recombinant proteins and in vitro binding assays. Myc-tagged 
Pellino3s and Pellino3l (wild-type and mutants as described above) were 
cloned into the histidine-tagged vector pRSET-A (Invitrogen). The constructs 
were transformed into Escherichia coli cells, protein expression was induced by 
isopropyl β-d-thiogalactopyranoside and recombinant proteins were purified 
from cell lysates with nickel–nitrilotriacetic acid-agarose according to the 
manufacturer’s instructions (Qiagen). The purity and integrity of recombinant 
proteins were confirmed by SDS-PAGE followed by Coomassie staining, in 
addition to immunoblot analysis with anti-Myc (2276; Cell Signaling). For 
in vitro binding assays characterizing the binding of Pellino3 to partner pro-
teins, recombinant Myc-tagged Pellino3 (1 µg) was initially immunoprecipi-
tated in binding buffer (20 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 
0.2% (vol/vol) Igepal, 10% (wt/vol) glycerol and complete protease-inhibitor 
‘cocktail’) with anti-Myc (2 µg; 2276; Cell Signaling) and protein A–protein 
G beads (30 µl) or Ni+ beads (15 µl). The beads were washed five times with 
binding buffer and then incubated overnight at 4 °C with lysates (300 µl per 
well of six-well plates) from HEK293 cells that had been transfected to express 
Flag-tagged RIP2 or recombinant glutathione S-transferase–RIP2 (500 ng). 
Beads were subjected to serial washes with binding buffer followed by cen-
trifugation. Coprecipitated proteins were eluted in SDS-PAGE sample buffer 
(62.5 mM Tris-HCl, pH 6.8, 10% (wt/vol) glycerol, 2% (wt/vol) SDS, 0.7 M 
β-mercaptoethanol and 0.001% (wt/vol) bromophenol blue) and then analyzed 
by immunoblot .
In vitro ubiquitination assay. Recombinant Pellino3s (wild-type or mutants 
as described above; 0.5 µg) was incubated with recombinant RIP2 (400 ng), 
ubiquitin with substitution of all lysine residues except K63 or with the K63R 
substitution (4 µg), E1 (100 nM), UbcH13-Uev1a (500 nM) and a protease 
inhibitor mixture (EDTA-free) in 20 mM Tris-HCl, pH 8, containing 
2 mM MgCl2, 2 mM ATP and 100 mM NaCl. Reactions were incubated at 
30 °C for 2 h and terminated by the addition of 1% (wt/vol) SDS. Samples were 
heated to 95 °C for 5 min to dissociate RIP2 from any associated proteins and 
then were diluted tenfold in lysis buffer (20 mM Tris-HCl, pH 7.4, contain-
ing 150 mM NaCl, 1% (vol/vol) Igepal, 10% (wt/vol) glycerol, 50 mM NaF, 
1 mM Na3VO4, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 
complete protease-inhibitor ‘cocktail’ (Roche)) before immunoprecipitation 
and immunoblot analysis.
Analysis of human colon samples from patients with Crohn’s disease. Human 
subjects 18–80 years of age who were undergoing routine colonoscopy as part 
of their ongoing care were prospectively recruited for this study (approved by 
The Adelaide and Meath/St James’s Hospital Joint Ethics Committee). After 
informed consent was obtained, two additional biopsies were collected from 
the abnormal (inflamed) colonic or ileal segment of patients with IBD and 
from the left colon in control subjects. Biopsies (‘anonymous’; without iden-
tifying information) were ‘snap-frozen’ and stored at −80 °C for batch analy-
sis. Patient demographics, medical history, endoscopy findings and routine 
histology were recorded. A total of 30 subjects were enrolled: 19 (63%) with 
IBD and 11 (37%) controls. Of those 30, 14 (47%) were male and the mean 
age was 46 years ± 16.4 years. There were more women in the control group 
(7 of 11; 63%) than in the group with IBD (9 of 19; 47%; P < 0.05). The controls 
were slightly older (mean age, 54.16 years ± 16.2 years; range, 18–73 years) 
than were the patients with IBD (mean age, 43.9 years ± 16.2 years; range, 
25–73 years), but this did not reach statistical significance (P < 0.24). Control 
subjects were defined as subjects with a normal ileo-colonoscopy and negative 
histology. The control subjects did not have symptoms suggestive of IBD. Of 
the control subjects, 8 were undergoing colonoscopy for polyp surveillance 
and the remaining 3 had anemia. In the group with IBD, 14 had established 
Crohn’s disease (10 with ileo-colonic disease and 4 with isolated ileal disease 
(ileal and ileo-colonic diseases are two varieties of Crohn’s and represent the 
site of activity)) and 5 had ulcerative colitis. Among the patients with IBD, 
15 (79%) were on maintenance therapy for IBD, including 5 (26%) receiving 
adalimumab, 7 (37%) receiving aminosalycilic acid and 3 (16%) receiving oral 
steroids. By endoscopy, the inflammation was assigned a grade of ‘moderate’ 
for 6 (32%) of the patients with IBD and as ‘mild’ for the remaining 13 (68%) 
patients with IBD. Routine histology confirmed active inflammation in 12 
cases (63%). Histology was normal for all 11 control subjects.
Frozen biopsy samples were thawed and placed in cell lysis buffer (20 mM 
Tris-HCl, pH 7.4, containing 150 mM NaCl, 1% (vol/vol) Igepal, 10% (wt/vol) 
glycerol, 50 mM NaF, 1 mM Na3VO4, 1 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl fluoride and complete protease-inhibitor ‘cocktail’ (Roche)), 
followed by sonication. Cell lysates were centrifuged for 10 min at 14,000g for 
removal of cell debris and nuclei. Supernatants were assayed for protein con-
centration and lysate samples (50 µg) were resolved by SDS-PAGE, transferred 
to nitrocellulose membranes and analyzed by immunoblot with anti-Pellino3 
(generated in-house), anti-Nod2 (sc-56168; Santa Cruz), anti-XIAP (MAB822; 
R&D Systems), antibody to all cIAP proteins (MAB3400; R&D Systems) and 
anti-β-actin (loading control; AC-15; Sigma). For anti-Pellino3, immunoblot 
analysis was done in the absence or presence of the immunogenic peptide that 
was used to generate the anti-Pellino3, to ‘define’ the nonspecific binding of 
the antibody. Immunoreactivity was visualized by the Odyssey Imaging System 
(LI-COR Biosciences) or enhanced chemiluminescence.
Statistical analysis. Prism5 software (GraphPad Software) was used for all 
statistical tests. A P value of 0.05 was considered significant.
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